|会社名||Zogenix Inc. （ゾゲニクス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 ゾゲニックス(Zogenix Inc.)は希少と他の中枢神経系(CNS)障害患者の特殊臨床ニーズを満たすCNS療法の開発・商業化に従事する製薬会社である。同社の治療中心分野はてんかん及び関連発作性疾患である。同社のリード製品候補であるZX008はドラベ症候群に関する発作性疾患治療のための低用量フェンフルラミンである。ZX008は米国・欧州連合（EU）において、ドラベ症候群の治療向けの希少疾患薬剤指定を受ける。同社は精神分裂症の治療のための追加製品候補でリスペリドンを1ヶ月に1回、長期間注射可能のReldayを有する。Reldayはリスペリドンの持続型注射製剤である。リスペリドンは、13歳以上の成人及びティーンエイジャーの統合失調症と双極性障害の症状を治療するために使用される。同社はReldayのフェーズIプログラムを完成した。 ゾゲニクスは米国の製薬会社。鎮痛剤および中枢神経障害治療薬の開発と商業化に従事。主な製品には偏頭痛治療の非侵襲性注射用キット｢スマベルド―ズプロ(一般名：スマトリプタン)｣、および24時間投与を長期間続ける必要がある重度疼痛用治療薬｢ゾヒドロER(一般名：酒石酸水素ヒドロコドン徐放性カプセル)｣などがある。 Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.|
|本社所在地||5858 Horton Street Suite 455 Emeryville CA 94608 USA|
|代表者氏名||Cam L. Garner カム・L・ガーナー|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Zogenix Inc. revenues decreased from $9.8M to $0K. Net loss before extraordinary items increased 35% to $59M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and develpoment increase of 77% to $48M (expense) Selling General_Administrative Exp increase of 30% to $13.4M (expense).|
Recap: Zogenix Q4 Earnings 2022/02/28 15:42:01 Benzinga
Zogenix (NASDAQ: ZGNX ) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Zogenix missed estimated earnings by 11.36%, reporting an EPS of $-0.98 versus an … Full story available on Benzinga.com
Zogenix GAAP EPS of -$0.98 misses by $0.10, revenue of $26.6M beats by $0.2M 2022/02/28 13:10:58 Seeking Alpha
Zogenix press release (ZGNX): Q4 GAAP EPS of -$0.98 misses by $0.10.Revenue of $26.6M (+212.9% Y/Y) beats by $0.2M.
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results 2022/02/28 13:00:00 GlobeNewswire
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021.
Zogenix Inc Shares Approach 52-Week High - Market Mover 2022/02/16 06:15:43 Kwhen Finance
Zogenix Inc (ZGNX) shares closed today at 1.1% below its 52 week high of $26.57, giving the company a market cap of $1B. The stock is currently up 61.0% year-to-date, up 16.2% over the past 12 months, and up 171.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%. Trading Activity Trading volume this week was 74.2% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -793.4% The company's stock price performance over the past 12 months beats the peer average by -360.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to firstname.lastname@example.org. © 2020 Kwhen Inc.
SHAREHOLDER ALERT: WeissLaw LLP Reminds TLMD, ZGNX, SYTE, and EPAY Shareholders About Its Ongoing Investigations 2022/02/11 00:48:00 Benzinga
NEW YORK , Feb. 10, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 305 Broadway, 7 th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 email@example.com SOC Telemed, Inc. (NASDAQ: TLMD ) Full story available on Benzinga.com
SHAREHOLDER ALERT: WeissLaw LLP Reminds ZGNX, FLMN, MIME, and MCFE Shareholders About Its Ongoing Investigations 2022/01/27 01:41:00 Kwhen Finance
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today 2022/01/19 16:44:41 InvestorPlace
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal.
Xenon draws buyout speculation after Zogenix deal 2022/01/19 15:51:29 Seeking Alpha
Dealreporter flags Xenon Pharmaceuticals <
> as a potential acquisition target following the agreement between Zogenix < > and UCB under which the Belgian drugmaker offered
Why Zogenix Stock Is on Fire Today 2022/01/19 15:18:32 The Motley Fool
A buyout deal is lighting a fire underneath the biotech''s shares today.
Zogenix, Vivos lead healthcare gainers; Cardiff Oncology, Yumanity among losers 2022/01/19 15:05:08 Seeking Alpha
Zogenix ZGNX +68%. Vivos Therapeutics VVOS +33%. Cardiff Oncology CRDF -24%. Yumanity Therapeutics YMTX -17%.
Analysts Expect Zogenix, Inc. (NASDAQ:ZGNX) Will Announce Quarterly Sales of $28.78 Million 2021/12/24 09:16:41 Transcript Daily
Wall Street brokerages expect that Zogenix, Inc. (NASDAQ:ZGNX) will report $28.78 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Zogenixs earnings, with the highest sales estimate coming in at $39.00 million and the lowest estimate coming in at $25.00 million. Zogenix reported sales of $8.50 
Brokerages Set Zogenix, Inc. (NASDAQ:ZGNX) Price Target at $33.67 2021/12/12 13:38:42 Dakota Financial News
Zogenix, Inc. (NASDAQ:ZGNX) has been given an average recommendation of Buy by the eight ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year price 
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 ゾゲニクス ZGNX Zogenix Inc.）